ROG Share Price Performance
CHF 321.90
65.60 (25.60%)
3.2% overvalued intrinsic discount
CHF 311.78
Fair Value
Price CHF 321.90
AnalystConsensusTarget CHF 311.78
bazza CHF 302.06
AnalystLowTarget CHF 230.00
Fair ValueCHF 311.78
Share Pricen/a
Roche Holding AG Stock Price
- 4 Narratives written by author
- 0 Comments on narratives written by author
- 241 Fair Values set on narratives written by author
ROG Community Narratives
AN
Fair Value CHF 311.78 3.2% overvalued intrinsic discount
Diagnostics, Pipeline And Automation Will Fuel Future Success
1users have liked this narrative
0users have commented on this narrative
140users have followed this narrative
BA
Fair Value CHF 302.06 6.6% overvalued intrinsic discount
Roche Holding will see a 4.2576% revenue growth shaking the market
0users have liked this narrative
0users have commented on this narrative
13users have followed this narrative
AN
Fair Value CHF 230 40.0% overvalued intrinsic discount
Regulatory Scrutiny And Generic Competition Will Erode Pricing Power
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Roche Holding will see a 4.2576% revenue growth shaking the market
Valuation ### **Analyse der Roche Jahreszahlen 2024: Wachstum setzt sich fort, Herausforderungen bleiben_20250130 #### Zusammenfassung der Ergebnisse Roche hat für das Jahr 2024 ein solides Wachstum von 7 % auf 60,5 Mrd. CHF erzielt, was die Erwartungen leicht übertroffen hat.Read more
170
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
13users have followed this narrative
BA
CHF 302.06
6.6% overvalued intrinsic discount
bazza's Fair Value
Revenue
5.07% p.a.
Profit Margin
17.53%
Future PE
21.07x
Price in 2030
CHF 359.58
Diagnostics, Pipeline And Automation Will Fuel Future Success
Key Takeaways Expanding innovative diagnostics and advancing high-value biologics pipelines position Roche for strong global growth and resilient revenues across diverse markets. Strategic investments in automation, AI, and emerging markets drive margin expansion, lower costs, and reduce reliance on older, patent-sensitive products.Read more
326
users have viewed this narrative1users have liked this narrative
0users have commented on this narrative
140users have followed this narrative
AN
CHF 311.78
3.2% overvalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
1.51% p.a.
Profit Margin
24.66%
Future PE
17.04x
Price in 2028
CHF 349.25
Regulatory Scrutiny And Generic Competition Will Erode Pricing Power
Key Takeaways Intensifying global pricing reforms, increasing biosimilar competition, and mounting regulatory demands will significantly pressure Roche's revenue, margins, and long-term profitability. Rising R&D costs, disruptive new technologies, and shifting payer priorities threaten Roche's innovation pipeline and ability to sustain premium pricing for novel therapies.Read more
23
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
CHF 230
40.0% overvalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
-0.12% p.a.
Profit Margin
19.98%
Future PE
17.37x
Price in 2028
CHF 274.73
Secular Trends Will Expand Personalized Medicine And Diagnostics
Key Takeaways Accelerated Pharma pipeline launches and integration of innovative cell therapies could drive multi-year revenue and margin growth above consensus expectations. Leadership in diagnostics and precision medicine, backed by strong cash flow and digital investment, enables Roche to command pricing power and sustain superior shareholder returns.Read more
5
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
CHF 400.07
19.5% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
4.82% p.a.
Profit Margin
25.95%
Future PE
19.03x
Price in 2028
CHF 448.38
Trending Discussion
Recently Updated Narratives
BA
Roche Holding will see a 4.2576% revenue growth shaking the market
Fair Value: CHF 302.06 6.6% overvalued intrinsic discount
13 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
ROG: Pipeline Readouts And Commercial Execution Will Shape Balanced Risk Reward Ahead
Fair Value: CHF 311.78 3.2% overvalued intrinsic discount
140 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Regulatory Scrutiny And Generic Competition Will Erode Pricing Power
Fair Value: CHF 230 40.0% overvalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Roche Holding AG Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Jan 29, 2026
- 11.09
- 74.79%
- 14.85%
- 100.0%
About ROG
- Founded
- 1896
- Employees
- 103249
- CEO
- WebsiteView website
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions. The company was founded in 1896 and is based in Basel, Switzerland.
